

Dean W Felsher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8376396/dean-w-felsher-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

13,537
citations

56
h-index

115
g-index

172
ext. papers

15,754
ext. citations

10.4
avg, IF

6.39
L-index

#	Paper	IF	Citations
158	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.. <i>Nanotheranostics</i> , 2022 , 6, 243-255	5.6	0
157	Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols.. <i>ACS Medicinal Chemistry Letters</i> , 2022 , 13, 615-622	4.3	
156	Twist1 is required for the development of UVB-induced squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021 , 60, 342-353	5	0
155	Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging. <i>Advanced Materials</i> , 2021 , 33, e2006902	24	24
154	Amphiphilic Cyclopeptide-Dyes: Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging (Adv. Mater. 16/2021). <i>Advanced Materials</i> , 2021 , 33, 2170121	24	
153	Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. <i>Nature Biotechnology</i> , 2021 , 39, 357-367	44.5	39
152	Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. <i>Hepatology</i> , 2021 , 73, 2342-2360	11.2	14
151	A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation. <i>Scientific Reports</i> , 2021 , 11, 1341	4.9	2
150	The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	23
149	Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia. <i>Methods in Molecular Biology</i> , 2021 , 2318, 297-312	1.4	0
148	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. <i>Nature Communications</i> , 2020 , 11, 2860	17.4	16
147	and cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. <i>ELife</i> , 2020 , 9,	8.9	17
146	MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 21, 850-859	10.7	8
145	The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?. <i>Cancer Research</i> , 2020 , 80, 3799-3802	10.1	4
144	The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1887-1903	4	25
143	Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. <i>Scientific Reports</i> , 2019 , 9, 6428	4.9	11
142	Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. <i>Cell Chemical Biology</i> , 2019 , 26, 711-723.e14	8.2	60

141	A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 70, 1056-1058	17
140	Conditional Upregulation of IFN- γ Alone Is Sufficient to Induce Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2019 , 203, 835-843	5
139	The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. <i>Cell Metabolism</i> , 2019 , 30, 556-572.e5	52
138	Regulates the Stemness Pathway via and to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells. <i>Cancer Research</i> , 2019 , 79, 4015-4025	30
137	MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T-Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling. <i>Blood</i> , 2019 , 134, 730-730	
136	Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. <i>Scientific Reports</i> , 2019 , 9, 16775	5
135	The MYC oncogene is a global regulator of the immune response. <i>Blood</i> , 2018 , 131, 2007-2015	84
134	Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 47-60	19
133	The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. <i>Oncogene</i> , 2018 , 37, 5435-5450	115
132	O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4924-4937	24
131	MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies. <i>Blood</i> , 2018 , 132, 2619-2619	1
130	Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). <i>Oncotarget</i> , 2018 , 9, 5517-5528	26
129	Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma 2018 , 6, 125	32
128	MYC: Master Regulator of Immune Privilege. <i>Trends in Immunology</i> , 2017 , 38, 298-305	49
127	Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 4300-4305	72
126	MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. <i>Nature Communications</i> , 2017 , 8, 15770	40
125	DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. <i>Oncotarget</i> , 2017 , 8, 76898-76920	28
124	Oncogenes and the Initiation and Maintenance of Tumorigenesis 2017 , 143-157	

123	Affordable Cancer Medications Are Within Reach but We Need a Different Approach. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2194-5	2.2	1
122	MYC regulates the antitumor immune response through CD47 and PD-L1. <i>Science</i> , 2016 , 352, 227-31	33.3	651
121	Intratumoral Administration of the Immunotherapeutic Combination Anti-ctla4, Anti-cd137 and Anti-ox40: Comparison to Systemic Administration, Peri-Draining Lymph Node Injection, and Cellular Vaccine in a Mouse Lymphoma Model. <i>Blood</i> , 2016 , 128, 4172-4172	2.2	3
120	BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016 , 7, 26926-34	3.3	10
119	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. <i>Nature</i> , 2016 , 531, 253-7	50.4	367
118	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. <i>Leukemia Research</i> , 2016 , 50, 123-131	2.7	33
117	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015 , 36 Suppl 1, S254-96	4.6	176
116	The effect of environmental chemicals on the tumor microenvironment. <i>Carcinogenesis</i> , 2015 , 36 Suppl 1, S160-83	4.6	79
115	Cancer prevention and therapy through the modulation of the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S199-S223	12.7	201
114	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 6539-44	11.5	139
113	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. <i>Cell Metabolism</i> , 2015 , 22, 1009-19	24.6	152
112	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S276-S304	12.7	179
111	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015 , 125, 2293-306	15.9	251
110	ARF: connecting senescence and innate immunity for clearance. <i>Aging</i> , 2015 , 7, 613-5	5.6	3
109	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. <i>Oncotarget</i> , 2015 , 6, 3563-77	3.3	15
108	Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. <i>Cancer Cell</i> , 2014 , 25, 350-65	24.3	158
107	Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. <i>Nature Chemistry</i> , 2014 , 6, 519-26	17.6	314
106	An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. <i>Immunologic Research</i> , 2014 , 58, 282-91	4.3	12

105	Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. <i>Small</i> , 2014 , 10, 566-75, 417	11	112
104	MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. <i>Cancer Cell</i> , 2014 , 26, 262-72	24.3	132
103	Alteration of the lipid profile in lymphomas induced by MYC overexpression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10450-5	11.5	99
102	Activation of Cre recombinase alone can induce complete tumor regression. <i>PLoS ONE</i> , 2014 , 9, e107589	3.7	15
101	Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E3316-24	11.5	11
100	MYC activation is a hallmark of cancer initiation and maintenance. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014 , 4,	5.4	430
99	miR-17-92 explains MYC oncogene addiction. <i>Molecular and Cellular Oncology</i> , 2014 , 1, e970092	1.2	1
98	Inactivation of MYC reverses tumorigenesis. <i>Journal of Internal Medicine</i> , 2014 , 276, 52-60	10.8	34
97	Oncogene withdrawal engages the immune system to induce sustained cancer regression 2014 , 2, 24		15
96	Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 734, 91-107	3.6	26
95	Noncanonical roles of the immune system in eliciting oncogene addiction. <i>Current Opinion in Immunology</i> , 2013 , 25, 246-58	7.8	10
94	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013 , 59, 1007-13	13.4	127
93	CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. <i>Science Translational Medicine</i> , 2013 , 5, 170ra13	17.5	126
92	Role of MYCN in retinoblastoma. <i>Lancet Oncology</i> , 2013 , 14, 270-1	21.7	27
91	Characterization of MYC-induced tumorigenesis by in situ lipid profiling. <i>Analytical Chemistry</i> , 2013 , 85, 4259-62	7.8	30
90	A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1896-905	6.1	30
89	Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1495-509	5.9	7
88	Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. <i>Cancer Research</i> , 2013 , 73, 1821-30	10.1	52

87	In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth. <i>Computational and Mathematical Methods in Medicine</i> , 2013 , 2013, 802512	2.8	
86	Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 432-432	2.2	
85	Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. <i>Leukemia Research</i> , 2012 , 36, 98-103	2.7	53
84	High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation. <i>Lab on A Chip</i> , 2012 , 12, 2190-8	7.2	49
83	HIF-2 β suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. <i>Stem Cells</i> , 2012 , 30, 1685-95	5.8	54
82	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. <i>Clinical and Experimental Immunology</i> , 2012 , 167, 188-94	6.2	21
81	Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. <i>PLoS Genetics</i> , 2012 , 8, e1002650	6	78
80	Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. <i>Journal of Clinical Investigation</i> , 2012 , 122, 163-77	15.9	54
79	SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. <i>PLoS ONE</i> , 2012 , 7, e45119	3.7	87
78	"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. <i>Oncotarget</i> , 2012 , 3, 58-66	3.3	33
77	Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10513-10513	2.2	
76	Survival and death signals can predict tumor response to therapy after oncogene inactivation. <i>Science Translational Medicine</i> , 2011 , 3, 103ra99	17.5	34
75	Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. <i>PLoS ONE</i> , 2011 , 6, e19758	3.7	11
74	Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. <i>Journal of Biological Chemistry</i> , 2011 , 286, 11035-46	5.4	12
73	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 17432-7	11.5	33
72	MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. <i>Cancer Research</i> , 2011 , 71, 2286-97	10.1	132
71	MYC as a regulator of ribosome biogenesis and protein synthesis. <i>Nature Reviews Cancer</i> , 2010 , 10, 301-313	3.3	570
70	Hypoxia in models of lung cancer: implications for targeted therapeutics. <i>Clinical Cancer Research</i> , 2010 , 16, 4843-52	12.9	69

69	Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. <i>Cancer Research</i> , 2010 , 70, 9837-45	10.1	25
68	MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. <i>Genes and Cancer</i> , 2010 , 1, 597-604	2.9	79
67	PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. <i>Cancer Research</i> , 2010 , 70, 9022-30	10.1	38
66	Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. <i>Blood</i> , 2010 , 115, 4061-70	2.2	22
65	The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. <i>Genes and Development</i> , 2010 , 24, 1281-94	12.6	83
64	Noninvasive molecular imaging of c-Myc activation in living mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 15892-7	11.5	37
63	Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. <i>Molecular Therapy</i> , 2010 , 18, 161-70	11.7	35
62	CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. <i>Cancer Cell</i> , 2010 , 18, 485-98	24.3	250
61	Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 297-305	4	61
60	Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. <i>PLoS ONE</i> , 2010 , 5, e11367	3.7	15
59	Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na. <i>Blood</i> , 2010 , 116, 4010-4010	2.2	
58	Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. <i>PLoS ONE</i> , 2009 , 4, e7172	3.7	32
57	Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 4390-5	11.5	38
56	Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. <i>Hepatology</i> , 2009 , 49, 471-81	11.2	11
55	Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. <i>Angewandte Chemie - International Edition</i> , 2009 , 48, 7668-72	16.4	424
54	Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. <i>Nature Medicine</i> , 2009 , 15, 566-71	50.5	91
53	SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. <i>Bioconjugate Chemistry</i> , 2009 , 20, 742-9	6.3	23
52	The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. <i>American Journal of Pathology</i> , 2009 , 174, 891-7	5.8	65

51	An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. <i>Nature Medicine</i> , 2008 , 14, 979-84	50.5	184
50	A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. <i>Molecular Cancer</i> , 2008 , 7, 74	42.1	11
49	Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. <i>PLoS ONE</i> , 2008 , 3, e2493	3.7	37
48	Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. <i>Lymphatic Research and Biology</i> , 2008 , 6, 149-54	2.3	18
47	Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?. <i>Cancer Research</i> , 2008 , 68, 3081-6; discussion 3086	10.1	83
46	(18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1947-51	4.6	12
45	Combined analysis of murine and human microarrays and CHIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. <i>PLoS Genetics</i> , 2008 , 4, e1000090	6	67
44	Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. <i>Cancer Research</i> , 2008 , 68, 5132-42	10.1	79
43	Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. <i>PLoS ONE</i> , 2008 , 3, e2125	3.7	71
42	Tumor dormancy and oncogene addiction. <i>Apmis</i> , 2008 , 116, 629-37	3.4	32
41	HIF-dependent antitumorigenic effect of antioxidants in vivo. <i>Cancer Cell</i> , 2007 , 12, 230-8	24.3	410
40	Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. <i>Journal of Immunology</i> , 2007 , 178, 4315-21	5.3	33
39	Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1318-23	4.6	16
38	Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 15400-5	11.5	49
37	BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. <i>Cancer Research</i> , 2007 , 67, 11657-67	10.1	49
36	Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 13028-33	11.5	328
35	Inhibition of HMGCoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. <i>Blood</i> , 2007 , 110, 2674-84	2.2	49
34	Identifying critical signaling molecules for the treatment of cancer. <i>Recent Results in Cancer Research</i> , 2007 , 172, 5-24	1.5	2

33	Conditional transgenic models define how MYC initiates and maintains tumorigenesis. <i>Seminars in Cancer Biology</i> , 2006 , 16, 313-7	12.7	121
32	Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. <i>Cell Cycle</i> , 2006 , 5, 1808-11	4.7	23
31	MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. <i>Cancer Research</i> , 2006 , 66, 6598-605	10.1	82
30	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 16266-71	11.5	129
29	c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. <i>Genes and Development</i> , 2006 , 20, 2096-109	12.6	657
28	Nano-Fluidic Detection of Oncoprotein Signaling in Preclinical and Patient Lymphoma Samples.. <i>Blood</i> , 2006 , 108, 2527-2527	2.2	
27	ASPP2 Haploinsufficiency Promotes Tumor Formation in a Mouse Model.. <i>Blood</i> , 2006 , 108, 4333-4333	2.2	
26	Rehabilitation of cancer through oncogene inactivation. <i>Trends in Molecular Medicine</i> , 2005 , 11, 316-21	11.5	24
25	Conditionally MYC: insights from novel transgenic models. <i>Cancer Letters</i> , 2005 , 226, 95-9	9.9	37
24	Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. <i>Oncogene</i> , 2005 , 24, 6101-7	9.2	13
23	Getting at MYC through RAS. <i>Clinical Cancer Research</i> , 2005 , 11, 4278-81	12.9	29
22	Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. <i>Cancer Research</i> , 2005 , 65, 7159-68	10.1	134
21	Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. <i>Cancer Research</i> , 2005 , 65, 4471-4	10.1	83
20	Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. <i>Journal of Biological Chemistry</i> , 2005 , 280, 35713-22	5.4	43
19	Two Oncogenic Hits Are Required To Initiate Lymphomagenesis in Adult, but Not Neonatal Hosts.. <i>Blood</i> , 2005 , 106, 2604-2604	2.2	
18	Putting oncogenes into a developmental context. <i>Cancer Biology and Therapy</i> , 2004 , 3, 942-4	4.6	8
17	The human BCL6 transgene promotes the development of lymphomas in the mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 14198-203	11.5	68
16	Developmental context determines latency of MYC-induced tumorigenesis. <i>PLoS Biology</i> , 2004 , 2, e332	9.7	109

15	MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. <i>Nature</i> , 2004 , 431, 1112-7	50.4	689
14	Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. <i>Seminars in Cancer Biology</i> , 2004 , 14, 3-11	12.7	50
13	Reversibility of oncogene-induced cancer. <i>Current Opinion in Genetics and Development</i> , 2004 , 14, 37-42	4.9	63
12	Cooperation between MYC and BCL2 to Induce Lymphoma Is Uncovered in an Adult Context.. <i>Blood</i> , 2004 , 104, 1530-1530	2.2	
11	How Cancers Escape Their Oncogene Habit. <i>Cell Cycle</i> , 2003 , 2, 328-331	4.7	15
10	Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. <i>Blood</i> , 2003 , 101, 2797-803	2.2	110
9	Cancer revoked: oncogenes as therapeutic targets. <i>Nature Reviews Cancer</i> , 2003 , 3, 375-80	31.3	342
8	Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 9974-9	11.5	124
7	Pharmacological inactivation of MYC for the treatment of cancer. <i>Drug News and Perspectives</i> , 2003 , 16, 370-4		19
6	Sustained loss of a neoplastic phenotype by brief inactivation of MYC. <i>Science</i> , 2002 , 297, 102-4	33.3	553
5	c-Myc is a critical target for c/EBPalpha in granulopoiesis. <i>Molecular and Cellular Biology</i> , 2001 , 21, 3789-805	11.5	218
4	Reversible tumorigenesis by MYC in hematopoietic lineages. <i>Molecular Cell</i> , 1999 , 4, 199-207	17.6	721
3	c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. <i>Annals of the New York Academy of Sciences</i> , 1992 , 651, 467-9	6.5	3
2	Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons473-510		
1	MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies		1